ANI Pharmaceuticals Inc represents values of innovation, integrity, and quality in the pharmaceutical industry. With a strong corporate philosophy centered around customer focus, ANI Pharmaceuticals consistently strives to provide effective and affordable solutions for patients. The company's commitment to excellence is reflected in their rigorous research and development process, ensuring the production of safe and reliable pharmaceutical products. With a focus on growth and expansion, ANI Pharmaceuticals continues to create value for their customers, shareholders, and employees through their dedication to continuous improvement and strategic partnerships.

ANI Pharmaceuticals Inc is primarily present in the United States.

ANI Pharmaceuticals Inc has achieved several significant milestones. In recent years, the company successfully acquired a portfolio of 23 generic drug products from Teva Pharmaceuticals, further expanding its product offerings. ANI Pharmaceuticals also obtained approval from the U.S. Food and Drug Administration (FDA) for several Abbreviated New Drug Applications (ANDAs), enabling the company to bring numerous generic products to market. Furthermore, ANI Pharmaceuticals has made substantial progress in developing a pipeline of complex generic and branded pharmaceutical products. These achievements demonstrate the company's dedication to growth, innovation, and providing high-quality medications to patients.

ANI Pharmaceuticals Inc. is a leading pharmaceutical company with a rich history and strong background. Founded in 2001, ANI specializes in developing, manufacturing, and marketing prescription and over-the-counter (OTC) pharmaceuticals. The company focuses primarily on complex products, including controlled substances and niche generics. ANI Pharmaceuticals has made significant strides in the industry, expanding its product portfolio through strategic acquisitions and partnerships. With a commitment to quality and innovation, ANI has established itself as a reliable provider of high-quality medications. The company continues to grow and diversify its offerings, ensuring a positive impact on the healthcare market.

The main competitors of ANI Pharmaceuticals Inc in the market are companies such as Teva Pharmaceutical Industries Ltd, Mylan N.V., and Endo International plc. These companies also operate in the pharmaceutical industry and offer a variety of products and services that may overlap with ANI Pharmaceuticals. However, ANI Pharmaceuticals differentiates itself through its focus on developing and commercializing niche branded pharmaceuticals. By continuously innovating and expanding its product portfolio, ANI Pharmaceuticals strives to maintain a competitive edge in the market.

ANI Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

ANI Pharmaceuticals Inc's business model revolves around the development, manufacturing, and marketing of specialty pharmaceutical products. As a specialty pharmaceutical company, ANI focuses on niche therapeutic areas such as cardiovascular, dermatology, and central nervous system disorders. By leveraging its strong research and development capabilities, ANI identifies opportunities in the market, develops new products or acquires existing ones, and then manufactures and markets them. This business model allows ANI Pharmaceuticals Inc to provide innovative and high-quality medications to patients while maintaining sustainable growth and profitability in the pharmaceutical industry.

ANI Pharmaceuticals P/E-luku on 11,80.

ANI Pharmaceuticals KUV on 2,04.

AlleAktien Laatuscore ANI Pharmaceuticals on 5/10.

odotettu ANI Pharmaceuticals liikevaihto on 553,46 milj. USD.

odotettu ANI Pharmaceuticals voitto on 95,91 milj. USD.

ANI Pharmaceuticals Inc. is an American pharmaceutical company that is engaged in the development, manufacturing, and distribution of branded and generic drugs. The company is headquartered in Baudette, Minnesota and has a wide range of products in various sectors such as anti-infectives, cardiology, oncology, pain relief, and others. ANI Pharmaceuticals Inc. primarily focuses on the manufacturing of generics and offers a wide range of generic products, mainly distributed in the United States. They also offer contract manufacturing services for pharmaceutical products and have acquired licensing rights from other pharmaceutical companies. In addition, ANI Pharmaceuticals Inc. has a strong presence in the US market and continuously strives to expand its product portfolio and improve customer satisfaction.

ANI Pharmaceuticals maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea ANI Pharmaceuticals:lle tai yhtiö ei maksa osinkoa.

ANI Pharmaceuticals:n ISIN on US00182C1036.

ANI Pharmaceuticals:n WKN on A1W15D.

ANI Pharmaceuticals:n tunnus on ANIP.

Viimeisen 12 kuukauden aikana ANI Pharmaceuticals maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana ANI Pharmaceuticals maksanee ennusteiden mukaan 0 USD osingon.

ANI Pharmaceuticals:n tämänhetkinen osinkotuotto on .

ANI Pharmaceuticals maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

ANI Pharmaceuticals maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

ANI Pharmaceuticals kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän ANI Pharmaceuticals osingon 24.7.2024, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 24.7.2024.

Viimeisin osinko maksettiin 24.7.2024.

Vuonna 2023 ANI Pharmaceuticals maksoi 0 USD osinkoina.

ANI Pharmaceuticals:n osingot maksetaan USDssa.